Santen Pharmaceutical Co., Ltd. (4536)
Market Closed
10 Aug, 06:00
¥
1,943. 00
+10
+0.5173%
¥
475.33B Market Cap
19.29 P/E Ratio
68% Div Yield
1.01M Volume
0.57 Eps
¥ 1,933
Previous Close Want to track 4536 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
4536 closed yesterday higher at ¥1,943, an increase of 0.5173% from Friday's close, completing a monthly decrease of -7.5862% or -¥159.5. Over the past 12 months, 4536 stock gained 19.4957%.
4536 pays dividends to its shareholders, with the most recent payment made on Dec 01, 2025. The next announced payment will be in In 1 month on Sep 29, 2026 for a total of ¥21.
The last earnings report, released on May 11, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Santen Pharmaceutical Co., Ltd. has completed 1 stock splits, with the recent split occurring on Mar 27, 2015.
The company's stock is traded on 5 different exchanges and in various currencies, with the primary listing on JPX (JPY).
Santen Pharmaceutical Co., Ltd. (4536) FAQ
What is the stock price today?
The current price is ¥1,943.00.
On which exchange is it traded?
Santen Pharmaceutical Co., Ltd. is listed on JPX.
What is its stock symbol?
The ticker symbol is 4536.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 68%.
What is its market cap?
As of today, the market cap is 475.33B.
Has Santen Pharmaceutical Co., Ltd. ever had a stock split?
Santen Pharmaceutical Co., Ltd. had 1 splits and the recent split was on Mar 27, 2015.
Santen Pharmaceutical Co., Ltd. Profile
| Pharmaceuticals Industry | Healthcare Sector | Takeshi Ito CEO | JPX Exchange | JP3336000009 ISIN |
| JP Country | 3,968 Employees | 29 Sep 2026 Last Dividend | 27 Mar 2015 Last Split | - IPO Date |
Overview
Santen Pharmaceutical Co., Ltd. is a Japanese company with a global presence, focusing on the research and development, manufacture, and marketing of pharmaceuticals and medical devices. With a rich history dating back to 1890, Santen has established itself as a pioneer in the field, particularly in the area of ophthalmology. The company's mission is to improve the quality of life for patients worldwide by delivering innovative medical solutions for the treatment of various eye conditions, including glaucoma, ocular hypertension, dry eye, and more. Headquartered in Osaka, Japan, Santen continues to expand its reach and impact on the international healthcare market.
Products and Services
- Tafluprost/Timolol Maleate: A combination of a prostaglandin F2a derivative and a beta-adrenergic receptor blocker used for treating glaucoma and ocular hypertension.
- Netarsudil Mesilate and Latanoprost: A prostaglandin F2a derivative in marketing approval phase intended for the treatment of glaucoma and ocular hypertension.
- Sepetaprost: An advanced prostaglandin analogue eye drop, currently in phase 3 clinical trials, aimed at treating ocular hypertension and glaucoma.
- Latanoprost Ophthalmic Emulsion: Another prostaglandin F2a derivative filed for marketing approval specifically designed to treat glaucoma and ocular hypertension.
- Cyclosporin Ophthalmic Emulsion: Designed for the treatment of vernal keratoconjunctivitis, leveraging the immunosuppressive properties of cyclosporin.
- Diquafosol Sodium: A topical treatment for dry eye that works by stimulating tear production.
- Olodaterol Hydrochloride: A beta2 receptor agonist in early-stage development (phase 1/2a) for treating dry eye.
- Sirolimus Ophthalmic Suspension: Currently in phase 2a studies for treating Fuchs endothelial corneal dystrophy and meibomian gland dysfunction.
- Epinastine Hydrochloride: An antihistamine for allergic conjunctivitis, now filed for marketing approval.
- Atropine Sulfate: A non-selective muscarinic antagonist undergoing phase 2/3 clinical trials for myopia treatment.
- AFDX0250BS: A selective muscarinic M2 antagonist in phase 2a of clinical trials, being developed for myopia management.
- Ursodeoxycholic Acid: In phase 2a clinical trials for the treatment of presbyopia, showcasing the company's innovation in addressing age-related vision loss.
- Oxymetazoline Hydrochloride: A direct-acting alpha adrenergic receptor agonist in phase 3 for the treatment of ptosis, illustrating Santen's commitment to addressing a broad range of eye health issues.
Contact Information
Address: Grand Front Osaka Tower A
Phone: 81 6 7664 8621
Website: https://www.santen.com
